JIP
VKTX icon

Jaffetilchin Investment Partners’s Viking Therapeutics VKTX Stock Holding History

Jaffetilchin Investment Partners’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11
Closed -$696 – 1280
2024
Q3 		$696 Buy
+11
New +$645 ﹤0.01% 1281

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Jaffetilchin Investment Partners's VKTX Position: Q4 2024 in Review

Jaffetilchin Investment Partners sold out of Viking Therapeutics (VKTX) in Q4 2024, closing a stake of 11 shares — an estimated $696 sold.

Jaffetilchin Investment Partners first reported a position in VKTX in Q3 2024 and held it in 1 quarter. The position peaked at $696 in Q3 2024. 408 funds tracked by Wall St. Rank hold VKTX as of Q4 2024.

  • Jaffetilchin Investment Partners reported no remaining Viking Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Jaffetilchin Investment Partners sold 11 Viking Therapeutics shares in Q4 2024, an estimated $696.
  • Jaffetilchin Investment Partners first reported a position in Viking Therapeutics in Q3 2024 and held it in 1 quarter.
  • Jaffetilchin Investment Partners's Viking Therapeutics position peaked at $696 in Q3 2024.
  • 408 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2024.

Based on Jaffetilchin Investment Partners's 13F filing for Q4 2024, filed 13 Feb 2025.